We were delighted to speak to Laure Gossec (Sorbonne Université and Pitié-Salpétrière Hospital, Paris, France) about the 48-week results of the BE ACTIVE phase 2b study of bimekizumab in psoriatic arthritis (Clinical Trial Identifier: NCT02969525). The abstract ‘Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity‘ (ABSTRACT NUMBER: 0356) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- Could you tell us a little about bimekizumab and its mechanism of action? (0:15)
- Why are patient-reported outcomes (PROs) important and what are the most useful PROs in psoriatic arthritis? (0:37)
- Could you tell us a little about the BE ACTIVE study? (1:25)
- What were the major findings of the BE ACTIVE study? (2:09)
- How well did the PROs correlate with disease activity, and what are the implications of these findings for clinical practice? (3:07)
Disclosures: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
